Modality
mAb
MOA
CGRPant
Target
TNFα
Pathway
Apoptosis
GIST
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
Jun 2017
Phase 2Current
NCT05607520
797 pts·GIST
2017-06→TBD·Terminated
NCT07304070
492 pts·GIST
2023-05→TBD·Completed
1,289 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2
P2
Termina…
P2
Complet…
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05607520 | Phase 2 | GIST | Terminated | 797 | Mayo |
| NCT07304070 | Phase 2 | GIST | Completed | 492 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα |